Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations

The transcript discusses the Biden administration's policy allowing Medicare to negotiate drug prices, a significant achievement under the Inflation Reduction Act. This policy aims to reduce costs for Medicare beneficiaries, with potential savings of billions. However, the transition to the Trump administration raises questions about the continuation of these negotiations. The discussion also covers the inclusion of GLP-1 medications like Ozempic and Wegovi in the negotiation list, highlighting their impact on weight loss and the potential for Medicare to cover them for obesity. The future of these policies depends on the incoming administration's decisions.

What new insight or understanding did you gain from this video?